Dermatomyositis Clinical Trial
Official title:
Effects of High-intensity Interval Training (HIIT) Compared to Low-intensity Exercise in Patients With Recent Onset Polymyositis and Dermatomyositis - a Randomized Controlled Trial
Polymyositis and dermatomyositis are rare inflammatory systemic conditions. Reduced muscle
function is a cardinal symptom and lung involvement is very common. Knowledge of heart
involvement in these patients is very limited, as is knowledge of exercise effects in recent
onset, active disease.
The aim of this project is to investigate effects of high-intensity interval training (HIIT)
compared to standard low-intensity home exercise as to tolerance, physical capacity, quality
of life, depression, disease activity, inflammation, muscle mass/fat mass, muscle metabolism
and heart function in patients with recent onset, active polymyositis and dermatomyositis.
This is a randomized controlled trial. Muscle biopsies are taken at time of diagnosis and
after 12 weeks of exercise. Muscle biopsies will be analyzed as to baseline kynurenine
pathway, calcium release, gene expression and inflammatory infiltrates and as to changes in
these parameters following exercise. Muscle function (primary outcome), maximal oxygen
uptake, muscle mass/fat mass, disease activity, systolic and diastolic heart function, as
well as quality of life and depression is measured at baseline and after 12 weeks of
exercise. After all assessments, patients are randomized to HIIT or standard low-intensity
home exercise.
The HIIT group will perform 6 sets of 30-60 second biking bouts reaching 85-100% of maximal
heart rate, in combination with strength training, three days a week for 12 weeks. The
control group will perform a standardized home exercise program five days a week for 12
weeks. After 12 weeks, all assessments are preformed again. If the HIIT is well tolerated,
patients in the control group will be invited to HIIT exercise according to the same
protocol. Clinical assessments will be performed at 3, 6 and 9 months follow-up in an open
extension.
This study will improve our understanding of heart function, muscle metabolism as well as
tolerance and effects of intensive exercise as well as heart function early in the disease
course and could also improve treatment and prognosis in patients with polymyositis and
dermatomyositis.
Patients randomized to the HIIT protocol will train three days a week for 12 weeks. Before
exercise start participants will rate self-reported pain and fatigue on a visual analogue
scale and describe in own words information about possible changes in medication dose, any
side effects from medication as well as possible negative and positive effects from previous
exercise sessions, as well as physical activities performed since the previous exercise
session. Each exercise session starts with a 5-minut warm-up on about 50% of maximal heart
rate. Each HIIT set is between 30-60 seconds where loads are increased and the participant
bikes as fast as possible with the goal of reaching >85% of maximal heart rate. During the
2-minuts rest in-between HIIT sets the participant will rate self-reported exertion using the
Borg CR-10, 0-10 scale and the Borg RPE scale, 6-20.
When initiating the exercise period, participants start on three HIIT sets on a lower
intensity, gradually increasing to goal intensity during the first two weeks. Then the number
of sets are gradually increased to six sets.
After completing six HIIT sets the participants perform one set of 10 voluntary repetitions
maximum (VRM) resistance training of the deltoids using free weights and of the quadriceps
using free weights or a quadriceps curl machine, depending on degree of muscle weakness.
Every other week a new 10 VRM is tested and training loads are adapted. After completing each
set, the participant rates perceived muscle exertion on the Borg CR-10 scale. The program is
ended with stretching of trained muscle groups and rating of overall exertion during the
exercise session on the Borg RPE-scale.
Participants randomized to the control group will perform a standardized home exercise
program on an easy-to moderate intensity adapted to initial muscle weakness, five days a week
for 12 weeks. The program includes tasks for muscle groups targeted by myositis and takes
about 15 minutes to perform. In combination with the home exercise program the participants
walks 15 minutes on 60% of maximal heart rate. Participants fill out an exercise diary
commenting on loads and number of repetitions for each task.
Participants in both groups ware a Polar 330A heart rate monitor during each training
session. By synchronizing to a computer program all exercise data are stored in a cloud data
base and can be monitored regularly by the project investigator.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05833711 -
Study Evaluating Efficacy and Safety of Froniglutide (PF1801) in Patients With Idiopathic Inflammatory Myopathy
|
Phase 2 | |
Not yet recruiting |
NCT06284954 -
A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis
|
Phase 2 | |
Completed |
NCT01906372 -
Acthar in Treatment of Refractory Dermatomyositis and Polymyositis
|
Phase 2 | |
Completed |
NCT01813617 -
Outcome in Patients With Recent Onset Polymyositis and Dermatomyositis
|
N/A | |
Completed |
NCT01165008 -
Anakinra in Myositis
|
Phase 2/Phase 3 | |
Completed |
NCT00004357 -
Absorption of Corticosteroids in Children With Juvenile Dermatomyositis
|
Phase 2 | |
Recruiting |
NCT05832034 -
Add-on Intravenous Immunoglobulins in Early Myositis
|
Phase 2 | |
Recruiting |
NCT05979441 -
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
|
Phase 3 | |
Not yet recruiting |
NCT05027152 -
Muscle Function and Effects of Repetitive Task Training in Patients With Inflammatory Myopaties
|
N/A | |
Active, not recruiting |
NCT04723303 -
Phase 1 Study of ULSC in Patients With Polymyositis (PM) and Dermatomyositis (DM)
|
Early Phase 1 | |
Completed |
NCT03267277 -
Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis
|
Phase 2/Phase 3 | |
Recruiting |
NCT05437263 -
A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis
|
Phase 3 | |
Active, not recruiting |
NCT04044690 -
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)
|
Phase 3 | |
Recruiting |
NCT05523167 -
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06004817 -
Evaluation of Severity in Juvenile and Adult-onset Dermatomyositis
|
||
Completed |
NCT02043548 -
Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis
|
Phase 2 | |
Completed |
NCT03414086 -
Predictor of Clinical Response to Acthar in Myositis
|
||
Completed |
NCT04628936 -
Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM.
|
Phase 2 | |
Recruiting |
NCT03293615 -
Exercise Capacity of Patients With Dermatomyosis
|
N/A | |
Recruiting |
NCT06462768 -
Neutrophil Extracellular Traps in Different Forms of Systemic Sclerosis
|